1.Delayed Treatment of Capsaicin Produces Partial Motor Recovery by Enhancing Dopamine Function in MPP⁺-lesioned Rats via Ciliary Neurotrophic Factor
Kyoung In KIM ; Jeong Yeob BAEK ; Jae Yeong JEONG ; Jin Han NAM ; Eun Su PARK ; Eugene BOK ; Won Ho SHIN ; Young Cheul CHUNG ; Byung Kwan JIN
Experimental Neurobiology 2019;28(2):289-299
Transient receptor potential vanilloid subtype 1 (TRPV1) on astrocytes prevents ongoing degeneration of nigrostriatal dopamine (DA) neurons in MPP⁺-lesioned rats via ciliary neurotrophic factor (CNTF). The present study determined whether such a beneficial effect of astrocytic TRPV1 could be achieved after completion of injury of DA neurons, rather than ongoing injury, which seems more relevant to therapeutics. To test this, the MPP⁺-lesioned rat model utilized here exhibited approximately 70~80% degeneration of nigrostriatal DA neurons that was completed at 2 weeks post medial forebrain bundle injection of MPP⁺. TRPV1 agonist, capsaicin (CAP), was intraperitoneally administered. CNTF receptor alpha neutralizing antibody (CNTFRαNAb) was nigral injected to evaluate the role of CNTF endogenously produced by astrocyte through TRPV1 activation on DA neurons. Delayed treatment of CAP produced a significant reduction in amphetamine-induced rotational asymmetry. Accompanying this behavioral recovery, CAP treatment increased CNTF levels and tyrosine hydroxylase (TH) activity in the substantia nigra pars compacta (SNpc), and levels of DA and its metabolites in the striatum compared to controls. Interestingly, behavioral recovery and increases in biochemical indices were not reflected in trophic changes of the DA system. Instead, behavioral recovery was temporal and dependent on the continuous presence of CAP treatment. The results suggest that delayed treatment of CAP increases nigral TH enzyme activity and striatal levels of DA and its metabolites by CNTF endogenously derived from CAP-activated astrocytes through TRPV1, leading to functional recovery. Consequently, these findings may be useful in the treatment of DA imbalances associated with Parkinson's disease.
Animals
;
Antibodies, Neutralizing
;
Astrocytes
;
Capsaicin
;
Ciliary Neurotrophic Factor
;
Dopamine
;
Dopaminergic Neurons
;
Medial Forebrain Bundle
;
Models, Animal
;
Neurons
;
Parkinson Disease
;
Pars Compacta
;
Rats
;
Receptor, Ciliary Neurotrophic Factor
;
Tyrosine 3-Monooxygenase
2.Comparison of Two Sedation Protocols for Postoperative Intensive Care Unit Care after Head and Neck Reconstructive Surgery: Midazolam/Morphine versus Remifentanil Sedation.
Nak Joon LEE ; Jeon Yeob JANG ; Sung Yong CHOI ; Ki Nam PARK ; Chung Hwan BAEK ; Jun Seo PARK ; Sook Hyun PARK ; Han Sin JEONG
Korean Journal of Otolaryngology - Head and Neck Surgery 2014;57(3):172-177
BACKGROUND AND OBJECTIVES: In head and neck reconstructive surgery, the stability of vital signs is important for patient recovery and flap outcome. We aimed to determine the better sedation protocol by comparing two protocols, namaely, midazolam/morphine (MM)-based and remifentanil (RF)-based sedation protocols, in the immediate postoperative settings of head and neck reconstructive surgery. SUBJECTS AND METHOD: We retrospectively reviewed the medical data of patients who underwent reconstructive surgery after the ablation of head and neck cancer involving MM sedation (n=34) or RF sedation (n=28). Parameters related to vital signs, flap outcomes, occurrence of delirium, length of stay and nursing burden were compared between the groups. RESULTS: The length of stay at the intensive care unit and flap outcomes were similar in the two groups. However, blood pressure as measured by frequency of variation was more stable in the RF group than in the MM group. In addition, the number of medical calls from the attending nurse due to the fluctuation of vital signs was less in the RF group than in the MM group. CONCLUSION: RF-based sedation for the postoperative intensive care unit care after head and neck reconstructive surgery is more effective in cases where vital signs are less stable. This type of sedation may decrease the nursing burden for these patients.
Blood Pressure
;
Delirium
;
Free Tissue Flaps
;
Head and Neck Neoplasms
;
Head*
;
Humans
;
Intensive Care Units*
;
Critical Care*
;
Length of Stay
;
Neck*
;
Nursing
;
Postoperative Care
;
Retrospective Studies
;
Vital Signs
3.Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer
Hyung-Don KIM ; Jwa Hoon KIM ; Yeon-Mi RYU ; Danbee KIM ; Sunmin LEE ; Jaehoon SHIN ; Seung-Mo HONG ; Ki-Hun KIM ; Dong‐Hwan JUNG ; Gi‐Won SONG ; Dae Wook HWANG ; Jae Hoon LEE ; Ki Byung SONG ; Baek-Yeol RYOO ; Jae Ho JEONG ; Kyu-pyo KIM ; Sang-Yeob KIM ; Changhoon YOO
Cancer Research and Treatment 2021;53(1):162-171
Purpose:
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.
Materials and Methods:
A total of 52 BTC patients treated with palliative gemcitabine plus cisplatin were included. Multiplexed immunohistochemistry was performed on tumor tissues, and immune infiltrates were separately analyzed for the stroma, tumor margin, and tumor core.
Results:
The density of CD8+ T cells, FoxP3- CD4+ helper T cells, and FoxP3+ CD4+ regulatory T cells was significantly higher in the tumor margin than in the stroma and tumor core. The density of LAG3- or TIM3-expressing CD8+ T cell and FoxP3- CD4+ helper T cell infiltrates was also higher in the tumor margin. In extrahepatic cholangiocarcinoma, there was a higher density of T cell subsets in the tumor core and regulatory T cells in all regions. A high density of FoxP3- CD4+ helper T cells in the tumor margin showed a trend toward better progression-free survival (PFS) (p=0.092) and significantly better overall survival (OS) (p=0.012). In multivariate analyses, a high density of FoxP3- CD4+ helper T cells in the tumor margin was independently associated with favorable PFS and OS.
Conclusion
The tumor margin is the major site for the active infiltration of T cell subsets with higher levels of LAG3 and TIM3 expression in BTC. The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.
4.Efficacy and safety of entecavir plus carnitine complex (GODEX(R)) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
Dae Won JUN ; Byung Ik KIM ; Yong Kyun CHO ; Hong Ju KIM ; Young Oh KWON ; Soo Young PARK ; Sang Young HAN ; Yang Hyun BAEK ; Yong Jin JUNG ; Hwi Young KIM ; Won KIM ; Jeong HEO ; Hyun Young WOO ; Seong Gyu HWANG ; Kyu Sung RIM ; Jong Young CHOI ; Si Hyun BAE ; Young Sang LEE ; Young Suck LIM ; Jae Youn CHEONG ; Sung Won CHO ; Byung Seok LEE ; Seok Hyun KIM ; Joo Hyun SOHN ; Tae Yeob KIM ; Yong Han PAIK ; Ja Kyung KIM ; Kwan Sik LEE
Clinical and Molecular Hepatology 2013;19(2):165-172
BACKGROUND/AIMS: Carnitine and vitamin complex (Godex(R)) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients. METHODS: 130 treatment-naive patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months. RESULTS: Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-gamma secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment. CONCLUSIONS: ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.
Adult
;
Alanine Transaminase/blood
;
Antiviral Agents/*therapeutic use
;
Carnitine/*therapeutic use
;
DNA, Viral/analysis
;
Drug Therapy, Combination
;
Enzyme-Linked Immunospot Assay
;
Female
;
Guanine/*analogs & derivatives/therapeutic use
;
Hepatitis B Surface Antigens/blood
;
Hepatitis B e Antigens/blood
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/*drug therapy
;
Humans
;
Interferon-gamma/metabolism
;
Male
;
Middle Aged
;
Mitochondria/physiology
;
Treatment Outcome
;
Vitamin B Complex/*therapeutic use